Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

n 68,216 111,119

Total liabilities 1,837,350 1,535,435

Commitments and Contingencies

Stockholders' Equity

Preferred stock, authorized 5,000,000 shares,

$.01 par value, none issued or outstanding - -

Common stock, authorized 100,000,000 shares,

$.001 par value, 41,130,270 and 40,991,385

issued and outstanding as of June 30, 2008,

and December 31, 2007, respectively 41,130 40,991

Additional paid-in capital 70,601,489 69,945,666

Accumulated deficit (61,940,977) (57,834,638)

Total stockholders' equity 8,701,642 12,152,019

$10,538,992 $13,687,454

SCOLR Pharma, Inc.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

Revenues

Licensing fees $- $- $- $173,077

Royalty income 279,571 422,056 545,126 747,676

Research and

development income - - - 621,222

Total revenues 279,571 422,056 545,126 1,541,975

Operating expenses

Marketing and selling 191,047 225,374 428,739 475,256

Research and

development 1,197,321 1,377,499 2,080,533 3,173,374

General and

administrative 1,062,646 1,112,244 2,294,930 2,288,742

Total operating

expenses 2,451,014 2,715,11
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... NEW YORK, April 3 /PRNewswire-Asia-FirstCall/ -- China Agri-Business, ... agricultural,application products through its operating company in China, ... 31,2008. , Revenue for ... a,decrease of 3.8% as compared to $3,037,414 for ...
... CAMBRIDGE, Mass., April 3 Verenium Corporation (Nasdaq: ... development of high-performance specialty enzymes and next-generation cellulosic ... of Verenium,s demonstration-scale facility in Jennings, Louisiana, and ... with BP, Verenium is now consolidating its research ...
... tiny wires with a diameter as small as ... for devices of the future, both in technology like ... circuits for next generation of electronics. But in order ... must be precisely controlled, and researchers must better understand ...
Cached Biology Technology:China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3Researchers peer into nanowires to measure dopant properties 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... thousand species (give or take 1.3 million). That is ... the most precise calculation ever offered -- with 6.5 million ... of the total) dwelling in the ocean depths. Announced ... based on an innovative, validated analytical technique that dramatically narrows ...
... physics-based theory could give researchers a deeper understanding of ... polymers. This advance provides a better picture of how ... plastics and other polymeric materials. Kenneth S. Schweizer, ... science and engineering at the University of Illinois, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... is a hairpin primer labeled with ... and non-fluorescent quencher) and a 3 ... is identical to the UniPrimer provided ... (S7901) and is provided at a ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... The JASCO Model AS-2055 and AS-2057 ... greater productivity and,the highest possible level of ... to 384 well positions (microplate) for,laboratory automation ... rack for 84 micro-vials or the standard ...
Biology Products: